


Our oncology pipeline^{1,2}

We are advancing a diversified portfolio of product candidates with transformative potential to address cancer care across indications with high incidence ...




■ mRNA cancer immunotherapy ■ Targeted therapy ■ Next generation immunomodulator ■ Novel-novel combination

¹ More details on BioNTech's rights can be found in the [Annual Report 2025](#); ² BC = Breast cancer; CRC = Colorectal cancer; CRPC = Castration-resistant prostate cancer; EC = Endometrial cancer; EGFRm NSCLC = EGFR-mutant non-small cell lung cancer; ES-SCLC = Extensive-stage small cell lung cancer; HCC = Hepatocellular carcinoma; HNSCC = Head and neck squamous cell carcinoma; MPM = Malignant mesothelioma; NEN = Neuroendocrine neoplasm; NSCLC = Non-small cell lung cancer; PDAC = Pancreatic ductal adenocarcinoma; PROC = Platinum-resistant ovarian cancer; SCLC = Small cell lung cancer; TNBC = Triple negative breast cancer; ³ Partnered with Bristol Myers Squibb; ⁴ Trial is currently being conducted by or on behalf of BioNTech. Bristol Myers Squibb holds co-exclusive rights to pumitamidg; ⁵ Partnered with DualityBio; ⁶ Partnered with Genentech, a member of the Roche Group; ⁷ Partnered with OncoC4; ⁸ Partnered with MediLink Therapeutics; ⁹ Partnered with Genmab; ¹⁰ In collaboration with Regeneron; ¹¹ Trial ongoing in China only; Status: May 2026

Our infectious disease pipeline¹

... as well as for potential prevention or treatment of infectious diseases.



mRNA Antibody

¹² Partnered with University of Pennsylvania; ¹³ Partnered with Pfizer; ¹⁴ Partnered with Fosun Pharma; ¹⁵ Funded by the Gates Foundation; ¹⁶ Funded by the Coalition for Epidemic Preparedness Innovations (CEPI); Status: May 2026